Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data.

Abécassis J, Hamy AS, Laurent C, Sadacca B, Bonsang-Kitzis H, Reyal F, Vert JP.

PLoS One. 2019 Nov 7;14(11):e0224143. doi: 10.1371/journal.pone.0224143. eCollection 2019.

2.

Text Mining in Electronic Medical Records Enables Quick and Efficient Identification of Pregnancy Cases Occurring After Breast Cancer.

Labrosse J, Lam T, Sebbag C, Benque M, Abdennebi I, Merckelbagh H, Osdoit M, Priour M, Guerin J, Balezeau T, Grandal B, Coussy F, Bobrie A, Ferrer L, Laas E, Feron JG, Reyal F, Hamy AS.

JCO Clin Cancer Inform. 2019 Oct;3:1-12. doi: 10.1200/CCI.19.00031.

3.

Domain-invariant features for mechanism of action prediction in a multi-cell-line drug screen.

Boyd JC, Pinheiro A, Nery ED, Reyal F, Walter T.

Bioinformatics. 2019 Oct 14. pii: btz774. doi: 10.1093/bioinformatics/btz774. [Epub ahead of print]

PMID:
31608933
4.

Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F.

Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12.

PMID:
31515462
5.

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

Slembrouck L, Darrigues L, Laurent C, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Vincent Salomon A, Laas Faron E, Cynober T, Gentien D, Baulande S, Snel MH, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G.

Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. [Epub ahead of print]

6.

A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer.

Faucheux L, Grandclaudon M, Perrot-Dockès M, Sirven P, Berger F, Hamy AS, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F, Scholer-Dahirel A, Guillot-Delost M, Soumelis V.

Oncoimmunology. 2019 Jun 24;8(9):e1624130. doi: 10.1080/2162402X.2019.1624130. eCollection 2019.

7.

Innovative DIEP flap perfusion evaluation tool: Qualitative and quantitative analysis of indocyanine green-based fluorescence angiography with the SPY-Q proprietary software.

Girard N, Delomenie M, Malhaire C, Sebbag D, Roulot A, Sabaila A, Couturaud B, Feron JG, Reyal F.

PLoS One. 2019 Jun 25;14(6):e0217698. doi: 10.1371/journal.pone.0217698. eCollection 2019.

8.

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M.

ESMO Open. 2019 May 21;4(3):e000515. doi: 10.1136/esmoopen-2019-000515. eCollection 2019. No abstract available.

9.

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer.

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F, Dahmani A, Lameiras S, Reyal F, Frenoy O, Pousse Y, Reichen M, Woolfe A, Brenan C, Griffiths AD, Vallot C, Gérard A.

Nat Genet. 2019 Jun;51(6):1060-1066. doi: 10.1038/s41588-019-0424-9. Epub 2019 May 31.

PMID:
31152164
10.

Tubular and mucinous breast cancer: results of a cohort of 917 patients.

Roux P, Knight S, Cohen M, Classe JM, Mazouni C, Chauvet MP, Reyal F, Colombo PE, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G.

Tumori. 2019 Feb;105(1):55-62. doi: 10.1177/0300891618811282. Epub 2018 Dec 20.

PMID:
30900967
11.

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.

de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G.

Breast Cancer Res Treat. 2019 Jun;175(2):379-387. doi: 10.1007/s10549-019-05160-9. Epub 2019 Feb 13.

PMID:
30759288
12.

Segmentation of Nuclei in Histopathology Images by Deep Regression of the Distance Map.

Naylor P, Lae M, Reyal F, Walter T.

IEEE Trans Med Imaging. 2019 Feb;38(2):448-459. doi: 10.1109/TMI.2018.2865709.

PMID:
30716022
13.

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F.

J Clin Oncol. 2019 Mar 10;37(8):624-635. doi: 10.1200/JCO.18.00636. Epub 2019 Jan 31.

14.

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach.

Laas E, Hamy AS, Michel AS, Panchbhaya N, Faron M, Lam T, Carrez S, Pierga JY, Rouzier R, Lerebours F, Feron JG, Reyal F.

PLoS One. 2019 Jan 23;14(1):e0208807. doi: 10.1371/journal.pone.0208807. eCollection 2019.

15.

Author Correction: New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.

Sadacca B, Hamy AS, Laurent C, Gestraud P, Bonsang-Kitzis H, Pinheiro A, Abecassis J, Neuvial P, Reyal F.

Sci Rep. 2018 Dec 13;8(1):17945. doi: 10.1038/s41598-018-36812-3.

16.

Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.

Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E.

Breast Cancer Res Treat. 2019 Jan;173(1):111-122. doi: 10.1007/s10549-018-4944-2. Epub 2018 Sep 20.

PMID:
30238274
17.

Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.

Labrosse J, Abdennebi I, Thibault L, Laas E, Merckelbagh H, Morel C, Lam T, Lae M, Reyal F, Hamy AS.

Breast. 2018 Dec;42:61-67. doi: 10.1016/j.breast.2018.08.103. Epub 2018 Aug 28.

PMID:
30179779
18.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
19.

Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific.

Michea P, Noël F, Zakine E, Czerwinska U, Sirven P, Abouzid O, Goudot C, Scholer-Dahirel A, Vincent-Salomon A, Reyal F, Amigorena S, Guillot-Delost M, Segura E, Soumelis V.

Nat Immunol. 2018 Aug;19(8):885-897. doi: 10.1038/s41590-018-0145-8. Epub 2018 Jul 16.

PMID:
30013147
20.

Neoadjuvant treatment: the future of patients with breast cancer.

Reyal F, Hamy AS, Piccart MJ.

ESMO Open. 2018 May 17;3(4):e000371. doi: 10.1136/esmoopen-2018-000371. eCollection 2018. No abstract available.

21.

Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.

Arfi A, Baffert S, Soilly AL, Huchon C, Reyal F, Asselain B, Neffati S, Rouzier R, Héquet D.

BMJ Open. 2018 May 18;8(5):e020276. doi: 10.1136/bmjopen-2017-020276.

22.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
23.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

24.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F.

Br J Cancer. 2018 Mar 20;118(6):e14. doi: 10.1038/bjc.2018.4. Epub 2018 Feb 20.

25.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.

Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27.

PMID:
29374852
26.

Sentinel lymph node biopsy validation for large tumors.

Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, Lambaudie E.

Int J Surg. 2017 Dec;48:275-280. doi: 10.1016/j.ijsu.2017.10.077. Epub 2017 Nov 24.

PMID:
29175020
27.

New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.

Sadacca B, Hamy AS, Laurent C, Gestraud P, Bonsang-Kitzis H, Pinheiro A, Abecassis J, Neuvial P, Reyal F.

Sci Rep. 2017 Nov 9;7(1):15126. doi: 10.1038/s41598-017-14770-6. Erratum in: Sci Rep. 2018 Dec 13;8(1):17945.

28.

Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.

Forissier V, Tallet A, Cohen M, Classe JM, Reyal F, Chopin N, Mazouni C, Gimbergues P, Daraï E, Colombo PE, Azuar P, Lambaudie E, Houvenaeghel G.

Eur J Cancer. 2017 Dec;87:47-57. doi: 10.1016/j.ejca.2017.10.004. Epub 2017 Nov 3.

PMID:
29107861
29.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.

Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F.

Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.

PMID:
28911063
30.

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.

de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4.

PMID:
28780480
31.

[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].

Ngo C, Laé M, Ratour J, Hamel F, Taris C, Caly M, Le Cunff A, Reyal F, Kirova Y, Pierga JY, Vincent-Salomon A.

Bull Cancer. 2017 Jul - Aug;104(7-8):608-617. doi: 10.1016/j.bulcan.2017.05.002. Epub 2017 Jun 7. French.

PMID:
28595742
32.

Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).

Houvenaeghel G, Lambaudie E, Cohen M, Classe JM, Reyal F, Garbay JR, Giard S, Chopin N, Martinez A, Rouzier R, Daraï E, Colombo PE, Coutant C, Gimbergues P, Azuar P, Villet R, Tunon de Lara C, Barranger E, Sabiani L, Goncalves A.

Breast. 2017 Aug;34:24-33. doi: 10.1016/j.breast.2017.04.008. Epub 2017 May 3.

PMID:
28475932
33.

Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.

Héquet D, Huchon C, Baffert S, Alran S, Reyal F, Nguyen T, Combes A, Trichot C, Alves K, Berseneff H, Rouzier R.

Br J Cancer. 2017 May 23;116(11):1394-1401. doi: 10.1038/bjc.2017.114. Epub 2017 Apr 25.

34.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
35.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F.

PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017.

36.

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.

PMID:
28155054
37.

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.

Hamy AS, Bonsang-Kitzis H, Lae M, Moarii M, Sadacca B, Pinheiro A, Galliot M, Abecassis J, Laurent C, Reyal F.

PLoS One. 2016 Dec 22;11(12):e0167397. doi: 10.1371/journal.pone.0167397. eCollection 2016.

38.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.

Breast Cancer Res Treat. 2017 Jan;161(1):73-81. doi: 10.1007/s10549-016-4040-4. Epub 2016 Nov 2.

PMID:
27807808
39.

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.

Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, Rouzier R, Faure C, Garbay JR, Daraï E, Hudry D, Gimbergues P, Villet R, Lambaudie E.

Br J Cancer. 2016 Oct 25;115(9):1024-1031. doi: 10.1038/bjc.2016.283. Epub 2016 Sep 29.

40.

Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.

Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, Lambaudie E.

Eur J Cancer. 2016 Nov;67:106-118. doi: 10.1016/j.ejca.2016.08.003. Epub 2016 Sep 16.

PMID:
27640137
41.

No evidence for TSLP pathway activity in human breast cancer.

Ghirelli C, Sadacca B, Reyal F, Zollinger R, Michea P, Sirven P, Pattarini L, Martínez-Cingolani C, Guillot-Delost M, Nicolas A, Scholer-Dahirel A, Soumelis V.

Oncoimmunology. 2016 May 9;5(8):e1178438. doi: 10.1080/2162402X.2016.1178438. eCollection 2016 Aug.

42.

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.

Gosset M, Hamy AS, Mallon P, Delomenie M, Mouttet D, Pierga JY, Lae M, Fourquet A, Rouzier R, Reyal F, Feron JG.

PLoS One. 2016 Aug 5;11(8):e0159888. doi: 10.1371/journal.pone.0159888. eCollection 2016.

43.

Breast cancer in young women: Pathologic features and molecular phenotype.

Sabiani L, Houvenaeghel G, Heinemann M, Reyal F, Classe JM, Cohen M, Garbay JR, Giard S, Charitansky H, Chopin N, Rouzier R, Daraï E, Coutant C, Azuar P, Gimbergues P, Villet R, Tunon de Lara C, Lambaudie E.

Breast. 2016 Oct;29:109-16. doi: 10.1016/j.breast.2016.07.007. Epub 2016 Jul 29.

PMID:
27479041
44.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Hamy AS, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2016 Jul 7;11(7):e0159123. doi: 10.1371/journal.pone.0159123. eCollection 2016.

45.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

46.

Whole-genome profiling helps to classify phyllodes tumours of the breast.

Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, Couturier J.

J Clin Pathol. 2016 Dec;69(12):1081-1087. doi: 10.1136/jclinpath-2016-203684. Epub 2016 May 20.

PMID:
27207013
47.

Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.

Bonsang-Kitzis H, Sadacca B, Hamy-Petit AS, Moarii M, Pinheiro A, Laurent C, Reyal F.

Oncoimmunology. 2015 Jun 24;5(1):e1061176. eCollection 2016.

48.

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Laas E, Mallon P, Duhoux FP, Hamidouche A, Rouzier R, Reyal F.

PLoS One. 2016 Feb 19;11(2):e0148957. doi: 10.1371/journal.pone.0148957. eCollection 2016.

49.

[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].

Sénéchal C, Reyal F, Callet N, This P, Noguès C, Stoppa-Lyonnet D, Fourme E.

Bull Cancer. 2016 Mar;103(3):273-81. doi: 10.1016/j.bulcan.2016.01.001. Epub 2016 Feb 3. Review. French.

PMID:
26852151
50.

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X, Reyal F.

PLoS One. 2016 Feb 1;11(2):e0146474. doi: 10.1371/journal.pone.0146474. eCollection 2016.

Supplemental Content

Support Center